---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-008984"
form_type: "8-K"
ticker: "ACRS"
cik: "0001557746"
company_name: "Aclaris Therapeutics, Inc."
filed_at: "2025-06-30T23:59:59+00:00"
generated_at: "2026-05-18T12:47:30.139203+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "low"
source: SEC EDGAR
---

# Aclaris Therapeutics posts updated corporate presentation; no material changes discernible

## Summary
- Presentation includes corporate strategy and pipeline overview; no financial results or guidance changes disclosed.
- No other material events or financial updates reported in the 8-K filing.
- The presentation is available on the company's investor relations website.

## SEC filing metadata
- accession: 0001558370-25-008984
- form_type: 8-K
- ticker: ACRS
- cik: 0001557746
- company_name: Aclaris Therapeutics, Inc.
- filed_at: 2025-06-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557746/000155837025008984/0001558370-25-008984-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557746/000155837025008984/acrs-20250630x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-008984
- JSON: https://secwatch.observer/filing/0001558370-25-008984.json
- Plain text: https://secwatch.observer/filing/0001558370-25-008984.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.